You are here

Our science / Clinical Trials / Find a Trial / NCT00219544

Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

Back to Search Print Save as PDF Bookmark Trial

NCT00219544

Last updated on February 16, 2020
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Calgary, Alberta, T2N 4N1 Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuropathic Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain
caused by a lesion of the peripheral nervous system manifesting with sensory symptoms
and signs, for at least 6 months at screening.

- At baseline, subjects must have completed at least 4 daily pain diaries and must have
a mean weekly pain score equal or greater than 4.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy;
Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other
entrapment-related neuropathic pain (defined as pain associated with focal nerve
lesion produced by constriction or mechanical distortion of the nerve, within a
fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain
syndrome (type 1 and 2); Fibromyalgia.

NCT00219544
Pfizer
Completed
Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search
Descriptive Information
Brief Title  ICMJE Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Official Title  ICMJE A Randomized, Placebo-Controlled Trial of the Efficacy and Safety of Pregabalin in the Treatment of Subjects With Peripheral Neuropathic Pain
Brief Summary This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous system such as Diabetic peripheral Neuropathy and Postherpetic Neuralgia).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Neuropathic Pain
Intervention  ICMJE
  • Drug: Pregabalin (Lyrica)
    pregabalin 150mg/day (75mg BID)
  • Drug: Pregabalin (Lyrica)
    pregabalin 300 mg/day (150mg BID)
  • Drug: Pregabalin (Lyrica)
    pregabalin 600/day (300mg BID)
  • Drug: Placebo
    Placebo
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: Pregabalin (Lyrica)
  • Experimental: 2
    Intervention: Drug: Pregabalin (Lyrica)
  • Experimental: 3
    Intervention: Drug: Pregabalin (Lyrica)
  • Placebo Comparator: 4
    Intervention: Drug: Placebo
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 22, 2011) 		158
Original Enrollment  ICMJE
 (submitted: September 13, 2005) 		360
Actual Study Completion Date  ICMJE February 2008
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused by a lesion of the peripheral nervous system manifesting with sensory symptoms and signs, for at least 6 months at screening.
  • At baseline, subjects must have completed at least 4 daily pain diaries and must have a mean weekly pain score equal or greater than 4.

Exclusion Criteria:

  • Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy; Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other entrapment-related neuropathic pain (defined as pain associated with focal nerve lesion produced by constriction or mechanical distortion of the nerve, within a fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain syndrome (type 1 and 2); Fibromyalgia.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00219544
Other Study ID Numbers  ICMJE A0081084
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date November 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now